Chromagen, Inc. has announced an expansion of its existing agreement with Merck and Co. to develop and supply a broad range of novel pharmacogenomic assays. Chromagen will utilize its High Performance Signal Amplification (HPSA) platform technologies and StarBright fluorophores to develop assays for evaluating cell signaling pathways and genes that are emerging biological targets in Read more about Merck And Chromagen Expand Collaboration[…]